{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:42:55Z","timestamp":1760150575145,"version":"build-2065373602"},"reference-count":28,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Hepatic events can occur after discontinuing antiviral therapy. We investigated factors associated with hepatitis flares and hepatic decompensation after discontinuing tenofovir disoproxil fumarate (TDF) and entecavir (ETV). Hepatitis flares within 6 months and hepatic decompensation were compared between non-cirrhotic hepatitis B e antigen-negative patients after discontinuing TDF or ETV by using the Cox proportional hazard model. The cumulative rates of hepatitis flare at 6 months after discontinuing ETV and TDF were 2% and 19%, respectively (p &lt; 0.001). The respective rates of hepatic decompensation at 6 months were 0% and 7% (p = 0.009). Higher alanine aminotransferase (ALT) (AASLD criteria) at the end of treatment (EOT) (HR = 4.93; p = 0.001), an off-therapy dynamic change in HBV DNA (rapid rebound of HBV DNA from the nadir, \u22651 log10 IU\/mL per month) (HR = 10.7; p &lt; 0.001), and the discontinuation of TDF (HR = 6.44; p = 0.006) were independently associated with hepatitis flares within 6 months. Older age (HR = 1.06; p &lt; 0.001) and an off-therapy dynamic change in HBV DNA (HR = 3.26; p = 0.028) were independently associated with hepatic decompensation after the discontinuation of antiviral therapy. In summary, we demonstrated several factors associated with hepatitis flares and hepatic decompensation after discontinuing antiviral therapy in non-cirrhotic hepatitis B e antigen-negative patients.<\/jats:p>","DOI":"10.3390\/jcm12247565","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T03:03:33Z","timestamp":1702004613000},"page":"7565","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hepatitis Flares or Hepatic Decompensation after Discontinuation of Tenofovir Disoproxil Fumarate and Entecavir in Non-Cirrhotic Hepatitis B e Antigen-Negative Patients"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-4858","authenticated-orcid":false,"given":"Yi-Jie","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Public Health, College of Public Health, China Medical University, Taichung 406040, Taiwan"},{"name":"Department of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"},{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3346-7462","authenticated-orcid":false,"given":"Tsai-Chung","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Public Health, China Medical University, Taichung 406040, Taiwan"},{"name":"Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung 413305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Hsu","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Hsin","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szu-Chia","family":"Liao","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-2665","authenticated-orcid":false,"given":"Shou-Wu","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402202, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8993-3039","authenticated-orcid":false,"given":"Yen-Chun","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"},{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4097-4315","authenticated-orcid":false,"given":"Teng-Yu","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0887-6432","authenticated-orcid":false,"given":"Jun-Sing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402202, Taiwan"},{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J. Viral Hepat."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J. Hepatol."},{"unstructured":"World Health Organization (2023, August 10). Hepatitis B. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b.","key":"ref_3"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: Finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/infdis\/jiy697","article-title":"The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy","volume":"219","author":"Chen","year":"2019","journal-title":"J. Infect. Dis."},{"doi-asserted-by":"crossref","unstructured":"(2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","key":"ref_7","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.cgh.2022.07.005","article-title":"Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B","volume":"21","author":"Choi","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.14309\/ajg.0000000000002203","article-title":"Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results from a Large, International, Multiethnic Cohort of Patients with Chronic Hepatitis B (RETRACT-B Study)","volume":"118","author":"Hirode","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.cgh.2016.07.002","article-title":"Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients","volume":"14","author":"Jeng","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12072-022-10357-0","article-title":"Comparable outcomes of decompensated chronic hepatitis B patients treated with entecavir or tenofovir: An 8-year cohort study","volume":"16","author":"Lee","year":"2022","journal-title":"Hepatol. Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/liv.15140","article-title":"Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies","volume":"42","author":"Liu","year":"2022","journal-title":"Liver Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.cgh.2022.08.021","article-title":"The Role of Off-Therapy Viral Kinetics in the Timing and Severity of Flares in Hepatitis B e Antigen-Negative Patients","volume":"21","author":"Liu","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New Approaches to Chronic Hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N. Engl. J. Med."},{"doi-asserted-by":"crossref","unstructured":"Khanam, A., Chua, J.V., and Kottilil, S. (2021). Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression. Int. J. Mol. Sci., 22.","key":"ref_17","DOI":"10.3390\/ijms22115497"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1111\/j.1365-2893.2010.01428.x","article-title":"Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study","volume":"18","author":"Fung","year":"2011","journal-title":"J. Viral Hepat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"Kumar","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/apt.17614","article-title":"Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population-based cohort study","volume":"58","author":"Hsu","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cgh.2008.10.023","article-title":"Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients","volume":"7","author":"Wong","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"doi-asserted-by":"crossref","unstructured":"Tan, Y., Ye, Y., Zhou, X., Chen, L., and Wen, D. (2015). Age as a predictor of significant fibrosis features in HBeAg-negative chronic hepatitis B virus infection with persistently normal alanine aminotransferase. PLoS ONE, 10.","key":"ref_22","DOI":"10.1371\/journal.pone.0123452"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.humpath.2016.04.012","article-title":"Quantitative fibrosis estimation by image analysis predicts development of decompensation, composite events and defines event-free survival in chronic hepatitis B patients","volume":"55","author":"Bihari","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/cid\/civ860","article-title":"All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus","volume":"62","author":"Xu","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/jvh.13528","article-title":"The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients","volume":"28","author":"Huang","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12072-021-10159-w","article-title":"Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation","volume":"15","author":"Kuo","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/j.cgh.2020.04.048","article-title":"Associations of HBV Genotype B vs C Infection with Relapse After Cessation of Entecavir or Tenofovir Therapy","volume":"18","author":"Chiu","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/24\/7565\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:35:05Z","timestamp":1760132105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/24\/7565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":28,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["jcm12247565"],"URL":"https:\/\/doi.org\/10.3390\/jcm12247565","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2023,12,8]]}}}